Physiologic impact of low-dose dopamine on renal function in the early post renal transplant period

Transplantation

Volumn 79, Issue 11, 2005, Pages 1561-1567

  Dalton, Richard S J ^a,b   Webber, Joanne N ^a   Cameron, Colin ^a   Kessaris, Nicolas ^a   Gibbs, Paul G ^a   Tan, Lam Chin ^a   Walters, Marisia A ^a   Sadek, Sami A ^a   Datta, Avijit K ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b YEOVIL DISTRICT HOSPITAL   (United Kingdom)

Author keywords

Dopamine; Renal; Transplantation

Indexed keywords

CYCLOSPORIN A; DOPAMINE;

ADULT; AGED; ARTICLE; CADAVER DONOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; DRUG INFUSION; DRUG USE; EVALUATION; FEMALE; HEART RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; PARAMETER; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; SODIUM URINE LEVEL; TIME; URINE FLOW RATE;

ADULT; AGED; BLOOD PRESSURE; CADAVER; DIURESIS; DOPAMINE; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; TISSUE DONORS; TREATMENT OUTCOME;

EID: 20544440392     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000158431.81676.C4     Document Type: Article

References (32)

1. Murphy MB, Murray C, Shorten GD. Fenoldopam: A selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 2001; 345: 1548-1557.
2. Goldberg LI. Dopamine receptors and hypertension: Physiologic and pharmacologic implications. Am J Med 1984; 77(suppl 4A): 37-44.
3. Pollock DM, Arendshorst WJ. Tubuloglomerular feedback and blood flow autoregulation during DA1-induced renal vasodilation. Am J Physiol 1990; 258: F627-F635.
4. Girbes AR, Smit AJ, Meijer S, et al. Renal and endocrine effects of fenoldopam and metoclopramide in normal man. Nephron 1990; 56: 179-185.
5. Hughes JM, Beck TR, Rose CE, et al. Selective dopamine-1 receptor stimulation produces natriuresis by a direct tubular action. J Hypertens Suppl 1986; 4: S106-S108.
6. Bertorello A, Aperia A. Inhibition of proximal tubule Na(+)-K(+)-ATPase activity requires simultaneous activation of DA1 and DA2 receptors. Am J Physiol 1990; 259: F924-F928.
7. D'Orio V, El Allaf D, Juchmes J, et al. The use of low-dose dopamine in in tensive care medicine. Arch Int Physiol Biochem 1984; 92(suppl): S11-S20.
8. Kellum JA. The use of diuretics and dopamine in acute renal failure: A systematic review of evidence. Crit Care 1997; 1: 53-59.
9. Marik PE. Low-dose dopamine: A systematic review. Intensive Care Med 2002; 28: 877-883.
10. Kellum JA, Decker JM. Use of dopamine in acute renal failure: A meta-analysis. Crit Care Med 2001; 29: 1526-1531.
11. Ferguson CJ, Hillis AN, Williams JD, et al. Calcium-channel blockers and other factors influencing delayed function in renal allografts. Nephrol Dial Transplant 1990; 5: 816-820.
12. World Medical Association. Recommendations guiding physicians in biomedical research involving human subjects. World Medical Association Declaration of Helsinki. J Med Liban 1994; 42: 88-89.
13. McDonald RH, Goldberg LI, McNay JL, et al. Effects of dopamine in man: Augmentation of sodium excretion, glomerular filtration rate and renal plasma flow. J Clin Invest 1964; 43: 1116-1124.
14. Carey RM, Siragy HM, Ragsdale NV, et al. Dopamine-1 and dopamine-2 mechanisms in the control of renal function. Am J Hypertens 1990; 3: 595-635.
15. Olsen NV, Lund J, Jensen PF, et al. Dopamine, dobutamine, and dopexamine: A comparison of renal effects in unanaesthetised human volunteers. Anesthesiology 1993; 79: 685-694.
16. Eachempati SR, Reed RL. Use of creatinine clearances to monitor the effect of low-dose dopamine in critically ill surgical patients. J Surg Res 2003; 112: 43-48.
17. Flancbaum L, Dick M, Choban PS, et al. Effects of low-dose dopamine on urine output in oliguric, critically ill, renal transplant patients. Clin Transplant 1998; 12: 256-259.
18. Grundmann R, Kindler J, Meider G, et al. Dopamine treatment of human cadaver kidney graft recipients: A prospectively randomised trial. Klin Wochenschr 1982; 60: 193.
19. Spicer ST, Gruenewald S, Chapman JR, et al. Low-dose dopamine after kidney transplantation: Assessment by Doppler ultrasound. Clin Transplant 1999; 13: 479-483.
20. Moutabarrik A, Ishibashi M, Fukunaga M, et al. FK506 mechanism of nephrotoxicity: Stimulatory effect on endothelin secretion by cultured kidney cells. Transpl Int 1992; 5(suppl 1): S93-S97.
21. Olyaei AJ, de Mattos AM, Bennett WM. Immunosuppressant-induced nephropathy: Pathophysiology, incidence and management. Drug Saf 1999; 21: 471-488.
22. Merkus JW, Hilbrands LB, Hoitsma AJ, et al. Haemodynamic changes in human kidney allografts following administration of nifedipine: Assessment with Doppler spectrum analysis. Transpl Int 1992; 5(suppl 1): S17-S20.
23. Hansen JM, Fogh-Andersen N, Leyssac PP, et al. Glomerular and tubular function in renal transplant patients treated with and without ciclosporin A. Nephron 1998; 80: 450-457.
24. Kiberd BA. Cyclosporine-induced renal dysfunction in human renal allograft recipients. Transplantation 1989; 48: 965-969.
25. Stanek B, Kovarik J, Rasoul-Rockenschaub S, et al. Renin-angiotensin- aldosterone system and vasopressin in cyclosporine-treated renal allograft recipients. Clin Nephrol 1987; 28: 186-189.
26. Hughes JM, Beck TR, Rose CE, et al. The effect of selective dopamine-1 receptor stimulation on renal and adrenal function in man. J Clin Endocrinol Metab 1988; 66: 518-525.
27. Barrett RJ, Wright KF, Taylor DR, et al. Involvement of dopamine receptor sub-types in dopaminergic modulation of aldosterone secretion in rats. Life Sci 1987; 40: 1499-1506.
28. Holmes CL, Walkey KR. Low-dose dopamine in the ICU. Chest 2003; 123: 1266-1275.
29. Conte G, Sabbatini M, Napodano P, et al. Dopamine counteracts the acute renal effects of cyclosporin in normal subjects. Transplant Proc 1988; 20(suppl 3): 563.
30. Carmellini M, Romagnoli J, Gualionotti PC, et al. Dopamine lowers the incidence of delayed graft function in transplanted kidney patients treated with cyclosporine A. Transplant Proc 1994; 26: 2626-2629.
31. Sandberg J, Tyden G, Groth CG. Low-dose dopamine infusion following cadaveric renal transplantation: No effect on the incidence of ATN. Transplant Proc 1992; 24: 357.
32. Kadieva VS, Friedman L, Margolius LP, et al. The effect of dopamine on graft function in patients undergoing renal transplantation. Anesth Analg 1993; 76: 362-365.